Poly-gene fusion transcripts and chromothripsis in prostate cancer

2012 ◽  
Vol 51 (12) ◽  
pp. 1144-1153 ◽  
Author(s):  
Chunxiao Wu ◽  
Alexander W. Wyatt ◽  
Andrew McPherson ◽  
Dong Lin ◽  
Brian J. McConeghy ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Fusion ◽  
Fusion Transcripts

Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions

2019 ◽  
Vol 19 (5) ◽  
pp. 368-381 ◽  
Author(s):  
Linh N.K. Tran ◽  
Ganessan Kichenadasse ◽  
Pamela J. Sykes
Keyword(s):  
Prostate Cancer ◽  
Valproic Acid ◽  
Androgen Receptor ◽  
Gene Fusion ◽  
Combination Therapies ◽  
Slowing Down ◽  
Castration Resistant ◽  
Local Pca ◽  
End Stage ◽  
Fusion Products

Prostate cancer (PCa) is the most frequent cancer in men. The evolution from local PCa to castration-resistant PCa, an end-stage of disease, is often associated with changes in genes such as p53, androgen receptor, PTEN, and ETS gene fusion products. Evidence is accumulating that repurposing of metformin (MET) and valproic acid (VPA) either when used alone, or in combination, with another therapy, could potentially play a role in slowing down PCa progression. This review provides an overview of the application of MET and VPA, both alone and in combination with other drugs for PCa treatment, correlates the responses to these drugs with common molecular changes in PCa, and then describes the potential for combined MET and VPA as a systemic therapy for prostate cancer, based on potential interacting mechanisms.

NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Ki‐1 positive anaplastic large cell lymphomas

1996 ◽  
Vol 92 (4) ◽  
pp. 866-871 ◽  
Author(s):  
Ingrid Simonitsch ◽  
Eva Renate Panzer‐Gruemayer ◽  
Daniel W. Ghali ◽  
Andreas Zoubek ◽  
ThaddÄus Radaszkiewicz ◽  
...  
Keyword(s):  
Gene Fusion ◽  
Large Cell ◽  
Distinct Subgroup ◽  
Fusion Transcripts

784 TMPRSS2-ERG GENE FUSION DEFINES A METASTATIC PHENOTYPE OF PROSTATE CANCER

2009 ◽  
Vol 8 (4) ◽  
pp. 316
Author(s):  
S. Perner ◽  
M. Svensson ◽  
R. Hossain ◽  
J. Day ◽  
J. Groskopf ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Fusion ◽  
Metastatic Phenotype

PAX3-FKHR and PAX7-FKHR Gene Fusions Are Prognostic Indicators in Alveolar Rhabdomyosarcoma: A Report From the Children’s Oncology Group

2002 ◽  
Vol 20 (11) ◽  
pp. 2672-2679 ◽  
Author(s):  
Poul H.B. Sorensen ◽  
James C. Lynch ◽  
Stephen J. Qualman ◽  
Roberto Tirabosco ◽  
Jerian F. Lim ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Metastatic Disease ◽  
Gene Fusion ◽  
Bone Marrow Involvement ◽  
Alveolar Rhabdomyosarcoma ◽  
Outcome Analysis ◽  
Striking Difference ◽  
Gene Fusions ◽  
Fusion Transcripts ◽  
Increased Risk

PURPOSE: Alveolar rhabdomyosarcoma (ARMS) is an aggressive soft tissue malignancy of children and adolescents. Most ARMS patients express PAX3-FKHR or PAX7-FKHR gene fusions resulting from t(2;13) or t(1;13) translocations, respectively. We wished to confirm the diagnostic specificity of gene fusion detection in a large cohort of RMS patients and to evaluate whether these alterations influence clinical outcome in ARMS. PATIENTS AND METHODS: We determined PAX3-FKHR or PAX7-FKHR fusion status in 171 childhood rhabdomyosarcoma (RMS) patients entered onto the Intergroup Rhabdomyosarcoma Study IV, including 78 ARMS patients, using established reverse transcriptase polymerase chain reaction assays. All patients received central pathologic review and were treated using uniform protocols, allowing for meaningful outcome analysis. We examined the relationship between gene fusion status and clinical outcome in the ARMS cohort. RESULTS: PAX3-FKHR and PAX7-FKHR fusion transcripts were detected in 55% and 22% of ARMS patients, respectively; 23% were fusion-negative. All other RMS patients lacked transcripts, confirming the specificity of these alterations for ARMS. Fusion status was not associated with outcome differences in patients with locoregional ARMS. However, in patients presenting with metastatic disease, there was a striking difference in outcome between PAX7-FKHR and PAX3-FKHR patient groups (estimated 4-year overall survival rate of 75% for PAX7-FKHR v 8% for PAX3-FKHR; P = .0015). Multivariate analysis demonstrated a significantly increased risk of failure (P = .025) and death (P = .019) in patients with metastatic disease if their tumors expressed PAX3-FKHR. Among metastatic ARMS, bone marrow involvement was significantly higher in PAX3-FKHR–positive patients. CONCLUSION: Not only are PAX-FKHR fusion transcripts specific for ARMS, but expression of PAX3-FKHR and PAX7-FKHR identifies a very high-risk subgroup and a favorable outcome subgroup, respectively, among patients presenting with metastatic ARMS.

scholarly journals Significance of the TMPRSS2:ERG gene fusion in prostate cancer

2017 ◽  
Vol 16 (4) ◽  
pp. 5450-5458 ◽  
Author(s):  
Zhu Wang ◽  
Yuliang Wang ◽  
Jianwen Zhang ◽  
Qiyi Hu ◽  
Fan Zhi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Fusion

scholarly journals The TMPRSS2–ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition

2015 ◽  
Vol 14 (8) ◽  
pp. 1896-1906 ◽  
Author(s):  
Payel Chatterjee ◽  
Gaurav S. Choudhary ◽  
Turkeyah Alswillah ◽  
Xiahui Xiong ◽  
Warren D. Heston ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Gene Fusion ◽  
Nonhomologous End Joining ◽  
Parp Inhibition ◽  
Prostate Cancer Cells ◽  
End Joining

scholarly journals Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer

Cell Reports ◽  
2016 ◽  
Vol 17 (10) ◽  
pp. 2620-2631 ◽  
Author(s):  
Ram S. Mani ◽  
Mohammad A. Amin ◽  
Xiangyi Li ◽  
Shanker Kalyana-Sundaram ◽  
Brendan A. Veeneman ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Prostate Cancer ◽  
Gene Fusion

Abstract 915: Pseudogene-associated recurrent gene fusion in prostate cancer

2019 ◽  
Author(s):  
Balabhadrapatruni V. S. K. Chakravarthi ◽  
Shanker Kalyana-Sundaram ◽  
Pavithra D. Arachchige ◽  
Shannon Carskadon ◽  
Satya S. Pathi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Fusion
Sign in / Sign up

Export Citation Format

Share Document